JPMorgan raised the firm’s price target on Syndax (SNDX) to $38 from $33 and keeps an Overweight rating on the shares. The firm updated models in the smid-cap biotechnology space.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.